(PharmaNewsWire.Com, July 29, 2021 ) According to the new market research report Interventional Cardiology Market size is projected to reach USD 21.2 billion by 2025 from USD 13.8 billion in 2020, at a CAGR of 8.9%.
The Growth in the Interventional Cardiology Devices Market is driven mainly by the rapid growth in the geriatric population and the associated increase in the prevalence of coronary artery diseases, approval of new and advanced products, and the growing preference for minimally invasive surgeries.
The old/normal balloons segment accounted for the largest share of the angioplasty balloons market in 2019.
Based on type, the angioplasty balloons market is segmented into old/normal balloons, cutting and scoring balloons, and drug-eluting balloons. In 2019, the old/normal balloons segment accounted for the largest share of the angioplasty balloons market. The large share of this segment can be attributed to a increasing its use in impating the stents and structural heart devices; and increasing prevalence of vaulvuloplasty.
Thrombectomy devices segment accounted for the largest share of the plaque modification devices market in 2019.
Based on type, the plaque modification devices market is segmented into atherectomy devices and thrombectomy devices. In 2019, the thrombectomy devices segment accounted for the largest share of the plaque modification devices market. Growth in this market segment can largely be attributed to the increasing incidence of blood clots and atrial embolisms across the globe.
North America accounted for the largest share of the interventional cardiology market in 2019.
North America accounted for the largest share of the interventional cardiology market in 2019. The large share of this segment can primarily be attributed to the rising incidence of cardiovascular diseases, the growing geriatric population, and the strong presence of industry players in the region.
Prominent players in the interventional cardiology devices market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Edward Lifescinces Corporation (US), Cardinal Health (US), iVascular (Spain), Becton, Dickinson, and Company (US), B. Braun Melsungen (Germany), Terumo Corporation (Japan), Biosensors International Group (Singapore), and BIOTRONIK SE & Co. KG (Germany).
Boston Scientific is the leading player in the interventional cardiology devices market. The company offers a wide range of guidewires, stents, catheters, angioplasty balloons, and structural heart devices. In the last three years, the company has been focusing on expanding its interventional cardiology portfolio by adopting various organic and inorganic strategies. Apart from this, the company has a strong presence in the US. As a result, in 2019, the company registered ~46% of its total interventional cardiology revenue from the US alone.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
